🔴 Novavax is trading 10.38% down today amid a broader biotech and market selloff

Novavax is trading at $9.54, down 10.38%, with sector-wide risk aversion the likeliest explanation for the decline.

• Q3 revenue was $68.3 million, beating estimates. Novavax raised its 2026 adjusted revenue outlook to $385 million–$415 million; these positive results do not explain the decline.
• A report linked the drop to a broader biotech selloff, with the biotech ETF down 3% at that time. Supplied sector context shows biotech down 5.19% and major indexes sharply lower.